# 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting

> **NCT00834587** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 5 mg/500 mg METAGLIP™ Tablets
- **DRUG:** 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets

## Key facts

- **NCT ID:** NCT00834587
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00834587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00834587, "5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00834587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*